-
1
Combination Immune Checkpoint Blockade Regimens for Previously Untreated Metastatic Renal Cell Carcinoma: The Winship Cancer Institute of Emory University Experience
Published 2022-08-01“…Methods: We performed a retrospective review of 49 mRCC patients treated with ICI-based combination regimens in the standard of care setting at the Winship Cancer Institute of Emory University from 2015–2020. …”
Get full text
Article -
2
-
3
Venetoclax ex vivo functional profiling predicts improved progression-free survival
Published 2022-08-01Get full text
Article -
4
-
5
-
6
Eliminating the monitoring period with subcutaneous daratumumab: a single-center experience
Published 2023-02-01Get full text
Article -
7
Electron transport chain activity is a predictor and target for venetoclax sensitivity in multiple myeloma
Published 2020-03-01Get full text
Article -
8
-
9
ERRATUM: Managing acute promyelocytic leukemia in patients belonging to the Jehovah’s Witness congregation
Published 2019-12-01Get full text
Article -
10
-
11
Cisplatin-mediated activation of glucocorticoid receptor induces platinum resistance via MAST1
Published 2021-08-01Get full text
Article -
12
-
13
-
14
Correction to: Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy
Published 2020-05-01Get full text
Article -
15
904 Repurposing CD26 (DPP4) inhibitors to enhance immunotherapy response in pancreatic ductal adenocarcinoma
Published 2021-11-01Article -
16
-
17
-
18
Managing acute promyelocytic leukemia in patients belonging to the Jehovah’s Witness congregation
Published 2017-09-01Get full text
Article -
19
Outcomes of Chronic Phase Chronic Myeloid Leukemia after Treatment with Multiple Tyrosine Kinase Inhibitors
Published 2020-05-01Get full text
Article -
20
Learning-Based Stopping Power Mapping on Dual-Energy CT for Proton Radiation Therapy
Published 2021-02-01Get full text
Article